| Schedule of Cash and Financial Assets Measured at Fair Value on a Recurring Basis |
The following tables present the Company’s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | June 30, 2025 | | Cost | | Unrealized Gains | | Accrued Interest | | Estimated Fair
Value | | Cash & Cash
Equivalents | | Investment
Securities | | | | | | | | | | | | | | Cash and cash equivalents, excluding money market accounts | $ | 72,772 | | $ | — | | $ | — | | $ | 72,772 | | $ | 72,772 | | $ | — | | | | | | | | | | | | | | Level 1: | | | | | | | | | | | | | Money market accounts | 28,922 | | — | | — | | 28,922 | | 28,922 | | — | | Government & agency securities | 20,047 | | 42 | | 78 | | 20,167 | | — | | 20,167 | | | | | | | | | | | | | | 48,969 | | 42 | | 78 | | 49,089 | | 28,922 | | 20,167 | | | | | | | | | | | | | | Level 2: | | | | | | | | | | | | Corporate bonds | 40,164 | | 199 | | 449 | | 40,812 | | — | | 40,812 | | | | | | | | | | | | | | Total | $ | 161,905 | | $ | 241 | | $ | 527 | | $ | 162,673 | | $ | 101,694 | | $ | 60,979 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | December 31, 2024 | | Cost | | Unrealized Gains (Losses) | | Accrued Interest | | Estimated Fair
Value | | Cash & Cash
Equivalents | | Investment
Securities | | | | | | | | | | | | | | Cash and cash equivalents, excluding money market accounts | $ | 77,551 | | $ | — | | $ | — | | $ | 77,551 | | $ | 77,551 | | $ | — | | | | | | | | | | | | | | Level 1: | | | | | | | | | | | | | Money market accounts | 13,377 | | — | | — | | 13,377 | | 13,377 | | — | | Government & agency securities | 28,920 | | 15 | | 96 | | 29,031 | | — | | 29,031 | | Equity securities | 10,000 | | (3,939) | | — | | 6,061 | | — | | 6,061 | | 52,297 | | (3,924) | | 96 | | 48,469 | | 13,377 | | 35,092 | | | | | | | | | | | | | | Level 2: | | | | | | | | | | | | | Corporate bonds | 35,771 | | 227 | | 326 | | 36,324 | | — | | 36,324 | | | | | | | | | | | | | | Total | $ | 165,619 | | $ | (3,697) | | $ | 422 | | $ | 162,344 | | $ | 90,928 | | $ | 71,416 | | | | | | | | | | | | |
|
| Schedule of Investment Losses |
The gains and losses related to the Company’s LifeMD investment for the three and six months ended June 30, 2025 and 2024 are summarized in the table below (in thousands): | | | | | | | | | | | | | | | | | | | Three months ended June 30, | | | | 2025 | | 2024 | | | | | | | | | | Net gains (losses) recognized during the period on equity securities | $ | 2,622 | | | $ | (4,188) | | | | | Less: Net gains recognized on equity securities sold | 2,622 | | | — | | | | | Unrealized losses recognized during the reporting period on equity securities still held at the reporting date | $ | — | | | $ | (4,188) | | | |
| | | | | | | | | | | | | Six months ended June 30, | | 2025 | | 2024 | | | | | | Net gains (losses) recognized during the period on equity securities | $ | 3,222 | | | $ | (1,750) | | | Less: Net gains recognized on equity securities sold | 3,222 | | | — | | | Unrealized losses recognized during the reporting period on equity securities still held at the reporting date | $ | — | | | $ | (1,750) | |
|